Roche, Basel, Switzerland, has entered into a strategic, long-term partnership with GE Healthcare, Chalfont St. Giles, United Kingdom, to develop and comarket digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
The two companies aim to develop an industry-first digital platform that will use advanced analytics to provide workflow solutions and applications in support of clinical decisionmaking. The collaboration seeks to allow the seamless integration and analysis of in vivo and in vitro data, patient records, guidelines for medical best practices, real-time monitoring, and the latest research outcomes. Clinicians will then have comprehensive decision support for providing the right treatment and quality of care for their patients.
For example, oncology care teams that include clinicians from multiple medical specialties can have a comprehensive dashboard that can be used to review, collaborate, and align treatment decisions for cancer patients at each stage of their disease. In the critical care setting, patient data from hospital monitoring equipment can be integrated with the patient’s biomarker, genomic, and sequencing data, helping physicians to identify, or even predict, severe complications before they strike.
“This unique partnership will deliver innovative solutions and insights in clinical decisionmaking,” says Roland Diggelmann, chief executive of Roche Diagnostics. “Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”
“This is the first time that two major players in healthcare have combined digital, in vivo, and in vitro diagnostics to this degree,” says Kieran Murphy, president and chief executive of GE Healthcare. “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients, and the healthcare industry.”
For more information, visit GE Healthcare and Roche.
